WINNIPEG, Manitoba, Jan. 16, 2017 (GLOBE NEWSWIRE) -- 3D Signatures Inc. (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) (the
"Company" or "3DS") is pleased to provide, in addition to its press release on December 22, 2016,
further details regarding its engagement of Kilmer Lucas Inc. (“Kilmer Lucas”).
Kilmer Lucas will provide 3DS with select Canadian and U.S. investor relations and strategic advisory services.
Employing an "outsourced in-house" partnership model, Kilmer Lucas designs and executes customized investor relations programs for
medical device, drug development, cell therapy, diagnostics and healthcare services companies.
Kilmer Lucas is an arm’s length third party to 3DS, and it does not have any interest, directly or indirectly,
in 3DS, or any right or intent to acquire such an interest. 3DS will pay Kilmer Lucas a monthly retainer fee of $7,500 for its
services. The agreement between 3DS and Kilmer Lucas has an initial term of 60 days, following which the agreement will renew
automatically for 30-day periods unless terminated by either party. Kilmer Lucas will be paid out of 3DS’ immediately available
funds.
About Kilmer Lucas
Kilmer Lucas is a healthcare-only investor relations and capital markets advisory company with offices in New
York, San Francisco and Toronto. It takes a holistic approach to building a customized investor relations strategy that begins with
a deep understanding of a company's corporate and financial goals. Kilmer Lucas seeks to leverage its longstanding relationships
and strong track record to positively influence investor perceptions, maximize stock valuations and lower the cost of capital
needed to fund its clients' growth. Kilmer Lucas also publishes its own popular healthcare investor news blog, BioTuesdays.
To-date, BioTuesdays has profiled more than 350 life sciences companies, providing invaluable exposure for innovative technologies
and compelling investment stories that may have otherwise gone unnoticed. More information about the firm can be found at www.kilmerlucas.com.
About 3DS
3DS (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) is a personalized medicine company with a proprietary software platform
based on the three-dimensional analysis of chromosomal signatures. The technology is well developed and supported by 16 clinical
studies on over 1,500 patients on 13 different cancers and Alzheimer’s disease. Depending on the desired application, the
technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is
designed to predict the course of disease and to personalize treatment for the individual patient. For more information, visit the
Company’s website at http://www.3dsignatures.com.
Forward-Looking Information
This news release includes forward-looking statements that are subject to assumptions, risks and
uncertainties. Forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that could
cause the actual results of the Company to be materially different from the historical results or from any future results expressed
or implied by such forward-looking statements. All statements within, other than statements of historical fact, are to be
considered forward looking. Forward-looking statements can generally be identified by the use of forwarding looking wording such as
"will", "may", "expect", "estimate", "anticipate", "intend", "believe" and "continue" or the negative thereof or similar
variations. In particular, the statements in this news release with respect to the benefits that will accrue to 3DS from its
association with Kilmer Lucas, the services to be provided by Kilmer Lucas, the costs to 3DS related to Kilmer Lucas’ services and
the length of 3DS’ engagement of Kilmer Lucas are forward-looking information. Although 3DS believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and
actual results or developments may differ materially from those in forward-looking statements. Risk factors and assumptions that
could cause actual results or outcomes to differ materially from the results expressed or implied by forward-looking information
include, among other things: the continuous renewal of the agreement with Kilmer Lucas; the ability to obtain all required
approvals; the state of the capital markets; market demand; technological changes that could impact the Company's existing products
or the Company's ability to develop and commercialize future products; competition; existing governmental legislation and
regulations and changes in, or the failure to comply with, governmental legislation and regulations; the ability to manage
operating expenses, which may adversely affect the Company's financial condition; the Company's ability to successfully maintain
and enforce its intellectual property rights and defend third-party claims of infringement of their intellectual property rights;
adverse results or unexpected delays in clinical trials; changes in legal, general economic and business conditions; and changes in
the regulatory regime. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to
rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking
statements.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information, please contact: Stephen Kilmer Investor Relations 647-872-4849 stephen@kilmerlucas.com or Hugh Rogers VP Corporate Finance 204-582-0922 investors@3dsignatures.com